Entera Bio reports $274.99 million offering completed under Form D

Entera Bio Ltd., a biotechnology company based in Jerusalem, Israel, filed a Form D with the SEC dated August 12, 2026, disclosing a completed private securities offering. The total offering amount and total amount sold were both listed at $274,999,976, reflecting an aggregate of 122,961,215 ordinary shares and 11,842,695 pre-funded warrants.¹

The date of first sale was listed as July 28, 2026.¹ The filing states that 53 investors had already invested in the offering.¹

The offering relied on an exemption under Rule 506(b) of Regulation D.¹ The securities offered included equity, an option, warrant or other right to acquire another security, a security to be acquired upon exercise of such a right, and pre-funded warrants along with underlying ordinary shares.¹

Six firms were listed as recipients of sales compensation. Leerink Partners LLC, based at 53 State Street, 40th Floor, Boston, Massachusetts, was one recipient.¹ Evercore Group L.L.C., located at 55 East 52nd Street, New York, New York, was another.¹ Guggenheim Securities, LLC, Cantor Fitzgerald & Co., LifeSci Capital, LLC, and Canaccord Genuity LLC were also listed as recipients, all with New York, New York addresses.¹

Sales commissions were estimated at $13,748,625, while finders' fees were listed as $0.¹ The filing indicated $0 of proceeds were used for payments to executive officers, directors, or promoters.¹

The Form D was signed by Chief Financial Officer Dana Yaacov-Garbeli on August 12, 2026.